Many targets and drugs are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease (NAFLD), but no one really knows which will turn out best for patients.
There is even a possibility researchers could turn to combinations of drugs with different mechanisms of action in order to produce an effective therapy, like hepatologists
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?